Usherwood Tim
The University of Sydney.
The George Institute for Global Health, Sydney.
Aust Prescr. 2024 Feb;47(1):15-19. doi: 10.18773/austprescr.2024.001.
Therapeutic inertia, sometimes referred to as clinical inertia, has been defined as failure to initiate or intensify therapy when therapeutic goals are not reached. Lack of initiation or intensification of treatment according to clinical guidelines has been linked to suboptimal control of a range of chronic conditions. Clinician factors contributing to therapeutic inertia include knowledge gaps; discomfort with uncertainty about the diagnosis, therapeutic target, or evidence; concerns about the safety of treatment intensification; and time constraints. Patient characteristics that may be associated with therapeutic inertia include male sex, older age, lower life expectancy, multiple comorbidities and clinical parameters that are close to target. There may be reasons other than therapeutic inertia that explain apparent undertreatment. Apparent inertia in prescribing may be accompanied by appropriate actions, such as provision of lifestyle advice or interventions to promote adherence to existing medication. Some patients choose not to intensify treatment. Interventions to reduce therapeutic inertia include access to evidence-based treatment guidelines and point-of-care tools, preferably integrated with clinical record systems; clinician education including educational visits; reminders; clinical audits with feedback and reflection on practice; shared decision-making; prompting by patients; and ambulatory or home monitoring (e.g. ambulatory blood pressure monitoring).
治疗惰性,有时也称为临床惰性,被定义为在未达到治疗目标时未能启动或强化治疗。根据临床指南未启动或强化治疗与一系列慢性病的控制不佳有关。导致治疗惰性的临床医生因素包括知识差距;对诊断、治疗目标或证据的不确定性感到不适;对强化治疗安全性的担忧;以及时间限制。可能与治疗惰性相关的患者特征包括男性、年龄较大、预期寿命较低、多种合并症以及接近目标的临床参数。可能存在除治疗惰性之外的其他原因来解释明显的治疗不足。处方中的明显惰性可能伴随着适当的行动,例如提供生活方式建议或干预措施以促进对现有药物的依从性。一些患者选择不强化治疗。减少治疗惰性的干预措施包括获取基于证据的治疗指南和即时医疗工具,最好与临床记录系统集成;临床医生教育,包括教育访问;提醒;进行临床审核并对实践进行反馈和反思;共同决策;患者提示;以及动态或家庭监测(例如动态血压监测)。